Cited 8 times since 2020 (1.6 per year) source: EuropePMC JACC. Basic to translational science, Volume 5, Issue 4, 25 4 2020, Pages 360-373 Therapeutic Antibody Against Phosphorylcholine Preserves Coronary Function and Attenuates Vascular <sup>18</sup>F-FDG Uptake in Atherosclerotic Mice. Ståhle M, Silvola JMU, Hellberg S, de Vries M, Quax PHA, Kroon J, Rinne P, de Jong A, Liljenbäck H, Savisto N, Wickman A, Stroes ESG, Ylä-Herttuala S, Saukko P, Abrahamsson T, Pettersson K, Knuuti J, Roivainen A, Saraste A
This study showed that treatment with a therapeutic monoclonal immunoglobulin-G1 antibody against phosphorylcholine on oxidized phospholipids preserves coronary flow reserve and attenuates atherosclerotic inflammation as determined by the uptake of 18F-fluorodeoxyglucose in atherosclerotic mice. The noninvasive imaging techniques represent translational tools to assess the efficacy of phosphorylcholine-targeted therapy on coronary artery function and atherosclerosis in clinical studies.
